Regeneron Pharmaceuticals reported stronger-than-expected second-quarter results, with revenue rising 4% year on year to $3.68 billion and adjusted earnings climbing 12% to $12.89 a share. Dupixent continued to power growth, while sales of the newer high-dose formulation of Eylea rose 29% to $393 million. Nonetheless, combined U.S. revenue for the Eylea franchise fell 25% to $1.14 billion as patients shifted away from the original 2-mg version and competition intensified. The earnings beat was overshadowed by fresh regulatory trouble. The U.S. Food and Drug Administration issued a second complete response letter for odronextamab, Regeneron’s bispecific antibody for relapsed or refractory follicular lymphoma, after citing deficiencies found during a July inspection of Catalent’s fill-finish plant in Bloomington, Indiana, recently acquired by Novo Nordisk. The same observations are expected to push back three separate August decision dates for Eylea HD, including a pre-filled syringe presentation. Chief Executive Officer Leonard Schleifer said the shortcomings are process-related and ‘have a good chance of being resolved expeditiously.’ In a separate setback for the sector, Allogene Therapeutics removed its conditioning antibody ALLO-647 from a pivotal CAR-T trial after a patient died from infection-related liver failure. The disclosure sent Allogene shares down roughly 11% and prompted JPMorgan to cut its rating to neutral.